Engineering the biomolecular corona could unlock the clinical potential of lipid nanoparticles for targeted, personalized nanomedicines beyond mRNA vaccines.
Researchers develop a groundbreaking silk peptide nanoparticle system for co-delivering erlotinib and curcumin, marking a significant advancement in targeted cancer therapy with the potential to overcome current treatment limitations.
Researchers demonstrate a hydrogel system possessing the ability to remember its shape, offering a unique platform for controlling cell adhesion behavior.
